Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. (CERE) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · CERE · as of Jun 9, 2026
Activity summary
Buy transactions
4
P-Purchase only
Sell transactions
27
12 Months
Buy/Sell ratio
0.15
Buy/Sell (by trades)
Overall sentiment
Cerevel Therapeutics Holdings, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
CERE insider buying and selling by quarter
CERE insider selling · CERE insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
CERE executive sell shares · CERE board member insider trading · CERE insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Aug 1, 2024 | PFIZER INC 10% Owner | Other | 27,349,211 | $1.23B⚡ | Form 4 |
| Aug 1, 2024 | BAIN CAPITAL INVESTORS LLC Director | Other | 65,679,781 | $2.96B⚡ | Form 4 |
| Aug 1, 2024 | Gordon Christopher R Director | Other | 3,282 | $148K | Form 4 |
| Aug 1, 2024 | Gordon Christopher R Director | Other | 65,679,781 | $2.96B⚡ | Form 4 |
| Aug 1, 2024 | Gordon Christopher R Director | Other | 10,461 | — | Form 4 |
| Aug 1, 2024 | Koppel Adam Director | Other | 3,282 | $148K | Form 4 |
| Aug 1, 2024 | Koppel Adam Director | Other | 65,679,781 | $2.96B⚡ | Form 4 |
| Aug 1, 2024 | Koppel Adam Director | Other | 10,461 | — | Form 4 |
| Aug 1, 2024 | Sanchez Ramiro Chief Medical Officer | Other | 14,673 | $660K | Form 4 |
| Aug 1, 2024 | Giordano Douglas E. Director | Other | 3,282 | $148K | Form 4 |
| Aug 1, 2024 | Giordano Douglas E. Director | Other | 10,461 | — | Form 4 |
| Aug 1, 2024 | Renaud Ronald C JR President & CEO · Director | Other | 83,857 | $3.77M⚡ | Form 4 |
| Aug 1, 2024 | Mckernan Ruth Director | Other | 3,282 | $148K | Form 4 |
| Aug 1, 2024 | Mckernan Ruth Director | Other | 10,461 | — | Form 4 |
| Aug 1, 2024 | Akamine Scott Chief Legal Officer | Other | 7,527 | $339K | Form 4 |
| Aug 1, 2024 | Sulzberger Gabrielle Director | Other | 48,415 | $2.18M⚡ | Form 4 |
| Aug 1, 2024 | Sulzberger Gabrielle Director | Other | 10,461 | — | Form 4 |
| Aug 1, 2024 | Renger John Chief Scientific Officer | Other | 6,370 | $287K | Form 4 |
| Aug 1, 2024 | DiPietro Kenneth Chief Human Resources Officer | Other | 25,042 | $1.13M⚡ | Form 4 |
| Aug 1, 2024 | Tregoning Kathleen See Remarks | Other | 10,666 | $480K | Form 4 |
| Aug 1, 2024 | DEKKERS MARIJN E Director | Other | 31,822 | $1.43M⚡ | Form 4 |
| Aug 1, 2024 | DEKKERS MARIJN E Director | Other | 402,326 | $18.10M⚡ | Form 4 |
| Aug 1, 2024 | DEKKERS MARIJN E Director | Other | 10,461 | — | Form 4 |
| Aug 1, 2024 | ALTSCHULLER Susan CFO | Other | 16,913 | $761K | Form 4 |
| Aug 1, 2024 | RIEDEL NORBERT G Director | Other | 46,092 | $2.07M⚡ | Form 4 |
BAIN CAPITAL INVESTORS LLC
Director
Date
Aug 1
Shares
65,679,781
Price
$45.00
Value
$2.96B ⚡
Gordon Christopher R
Director
Date
Aug 1
Shares
65,679,781
Price
$45.00
Value
$2.96B ⚡
Sanchez Ramiro
Chief Medical Officer
Date
Aug 1
Shares
14,673
Price
$45.00
Value
$660K
Renaud Ronald C JR
President & CEO · Director
Date
Aug 1
Shares
83,857
Price
$45.00
Value
$3.77M ⚡
Akamine Scott
Chief Legal Officer
Date
Aug 1
Shares
7,527
Price
$45.00
Value
$339K
Sulzberger Gabrielle
Director
Date
Aug 1
Shares
48,415
Price
$45.00
Value
$2.18M ⚡
Renger John
Chief Scientific Officer
Date
Aug 1
Shares
6,370
Price
$45.00
Value
$287K
DiPietro Kenneth
Chief Human Resources Officer
Date
Aug 1
Shares
25,042
Price
$45.00
Value
$1.13M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About CERE insider trading
CERE insider trades
Cerevel Therapeutics Holdings, Inc. (CERE) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including CERE. Over the past 12 months, 0 insiders have filed transactions with the SEC. CERE insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Cerevel Therapeutics Holdings, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
CERE insider trading · 5 questionsThe insiders of Cerevel Therapeutics Holdings, Inc. (CERE) include executives and directors such as CERE, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026